ASRS 2023: RETINAL VASCULAR DISEASE

Highlights From ASRS – Retinal Vascular Disease

Oct 23, 2023

ARSR Retinal Vascular Annual 2023.indd

Author

Rebecca Shover

View all posts

RETURN TO Highlights From ASRS – Retinal Vascular Disease

MORE FROM ASRS 2023: RETINAL VASCULAR DISEASE

Using OCTA Blood Flow Analysis to Detect Early Diabetic Retinopathy

Aug 07, 2023

Aflibercept 8 mg Vs 2 mg for Wet AMD: Safe & Better Outcomes

Jul 25, 2023

Varied Syringe Accuracy Affects Intravitreal Injection Safety

Jul 25, 2023

Elevating Diabetic Retinopathy Diagnosis: The Potential of OCTA Bloodflow Analysis

Jul 25, 2023

Promising Outcomes With Aflibercept for Diabetic Macular Edema: The PHOTON Trial

Jul 25, 2023

ASRS Satellite Symposia

Jul 24, 2023

ASRS 2023: RETINAL VASCULAR DISEASE

Aflibercept 8 mg Provides Vision Gains With Fewer Injections in DME

Among patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (AMD), reducing the treatment burden of frequent injections...

Racial & Ethnic Diversity Lacking in Diabetic Retinopathy Trials

“Jennifer Pinal, a co-author on this study and a current Latinx medical student from the community we serve, and I...

Aflibercept 8 mg Provides “Greater Therapeutic Benefit” in Neovascular AMD

Compared with 2 mg, aflibercept 8 mg administered at varying intervals was more effective, with comparable safety, according to results...

ASRS 2023: RETINAL VASCULAR DISEASE

Highlights From ASRS – Retinal Vascular Disease

MORE FROM ASRS 2023: RETINAL VASCULAR DISEASE

Using OCTA Blood Flow Analysis to Detect Early Diabetic Retinopathy

Aflibercept 8 mg Vs 2 mg for Wet AMD: Safe & Better Outcomes

Varied Syringe Accuracy Affects Intravitreal Injection Safety

Elevating Diabetic Retinopathy Diagnosis: The Potential of OCTA Bloodflow Analysis

Promising Outcomes With Aflibercept for Diabetic Macular Edema: The PHOTON Trial

ASRS Satellite Symposia

ASRS 2023: RETINAL VASCULAR DISEASE

Aflibercept 8 mg Provides Vision Gains With Fewer Injections in DME

Racial & Ethnic Diversity Lacking in Diabetic Retinopathy Trials

Aflibercept 8 mg Provides “Greater Therapeutic Benefit” in Neovascular AMD

PW Weekly Newsletters

MORE FROM ASRS 2023: Retinal Vascular Disease

Using OCTA Blood Flow Analysis to Detect Early Diabetic Retinopathy

Aflibercept 8 mg Vs 2 mg for Wet AMD: Safe & Better Outcomes

Varied Syringe Accuracy Affects Intravitreal Injection Safety

Elevating Diabetic Retinopathy Diagnosis: The Potential of OCTA Bloodflow Analysis

Promising Outcomes With Aflibercept for Diabetic Macular Edema: The PHOTON Trial

ASRS Satellite Symposia

Follow Us

ASRS 2023: RETINAL VASCULAR DISEASE

Highlights From ASRS – Retinal Vascular Disease

Author

MORE FROM ASRS 2023: RETINAL VASCULAR DISEASE

ASRS 2023: RETINAL VASCULAR DISEASE

PW Weekly Newsletters

MORE FROM ASRS 2023: Retinal Vascular Disease

Stay connected to the latest news with Physician’s Weekly